Lacosamide

Hospital Pharmacy

Volumn 44, Issue 6, 2009, Pages 497-508

  Cada, Dennis J ^b   Levien, Terri L ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Washington State University Spokane ^*

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLONAZEPAM; DIGOXIN; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; METFORMIN; OMEPRAZOLE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ATAXIA; BALANCE DISORDER; BLURRED VISION; DIABETIC NEUROPATHY; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; FATIGUE; FOCAL EPILEPSY; HEADACHE; HUMAN; MEMORY DISORDER; NAUSEA; NYSTAGMUS; REVIEW; SEIZURE; SOMNOLENCE; SYNCOPE; TREMOR; VERTIGO; VOMITING;

EID: 67651120028     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4406-497     Document Type: Review

References (51)

1. Vimpat [package insert]. Smyrna, GA: UCB, Inc; October 2008.
2. UCB announces FDA filing for laco - samide in the treatment of partial onset seizures in adults with epilepsy [news release]. Brussels, Belgium: UCB, Inc; November 29, 2007. http://www.ucb .com/news/2810.asp. Accessed January 15, 2008.
3. UCB announces FDA filing for lacosa - mide in the treatment of diabetic neuropathic pain [news release]. Brussels, Belgium: UCB, Inc; November 29, 2007. http://www.ucb.com/news/2809.asp. Accessed January 15, 2008.
4. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partialonset seizures. Epilepsia. 2007;48(7): 1308-1317. (Pubitemid 47063096)
5. Freitag J, Beyreuther B, Heers C, Stoehr T. Lacosamide modulates response mediator protein 2 (CRMP-2) [abstract]. Epilepsia. 2007;48(suppl 6):320.
6. Freitag J, Beyreuther B, Heers C, Stoehr T. Lacosamide modulates collapsin response mediator protein 2 (CRMP-2) [abstract]. Neurology. 2007; 68(suppl 1):A125.
7. Heers C, Lees G, Errington A, Stoehr T. Lacosamide selectively enhances sodium channel slow inactivation [abstract]. Epilepsia. 2007;48(suppl 6):320.
8. Heers C, Beyreuther B, Freitag J, Lees G, Errington A, Stoehr T. Lacosamide selectively enhances sodium channel slow inactivation [abstract]. Neurology. 2007; 68(suppl 1):A266.
9. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73(1): 157-169. (Pubitemid 350294207)
10. Stoehr T, Heers C, Stables J, Wilcox K, White S. Preclinical profile of the novel anticonvulsant lacosamide [abstract]. Epilepsia. 2006;47(suppl 3):84-85.
11. Errington AC, Coyne L, Stohr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology. 2006; 50(8):1016-1029. (Pubitemid 43794912)
12. Stoehr T, Shandra P, Kashenko O, Shandra A. Synergism of lacosamide and first-generation and novel antiepileptic drugs in the 6 Hz seizure model in mice [abstract]. Epilepsia. 2007;48(suppl 6): 252.
13. Stoehr T, Stables JP, Wilcox K, White HS. The pre-clinical profile of the novel anticonvulsant lacosamide [abstract]. Epilepsia. 2005;46(suppl 6):373-374
14. Stoehr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007;74(2-3):147-154.
15. Brandt C, Heile A, Potschka H, Stoehr T, Loscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdale kindling in rats. Epilepsia. 2006;47(11):1803-1809. (Pubitemid 44730049)
16. Duncan GE, Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res. 2005;67(1-2):81-87. (Pubitemid 41578983)
17. Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain. Arthritis Res Ther. 2007;9(1):R14. (Pubitemid 46336461)
18. Beyreuther BK, Callizot N, Brot MD, Feldman R, Bain SC, Stohr T. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur J Pharmacol. 2007; 565(1-3):98-104. (Pubitemid 46782774)
19. Beyreuther BK, Geis C, Stohr T, Sommer C. Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. Neuropharmacology. 2007;52(5):1312-1317. (Pubitemid 46527705)
20. Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol. 2006;539(1-2):64-70. (Pubitemid 43783512)
21. Hao JX, Stohr T, Selve N, Wiesenfeld-Hallin Z, Xu XJ. Lacosamide, a new antiepileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur J Pharmacol. 2006;553(1-3):135-140. (Pubitemid 44779609)
22. Freitag J, Stoehr T. Anti-tremor effects of the investigational antiepileptic drug lacosamide on harmaline-induced tremors in rats [abstract]. Eur J Neurology. 2006;13(suppl 2):87.
23. Stoehr T. Lacosamide has potent anti-tremor effects in a rat model for essential tremor [abstract]. Neurology. 2006;66(suppl 2):A253.
24. Stoehr T. Lacosamide reduces tardive dyskinesia in a mouse model [abstract]. Movement Dis. 2006;21(suppl 15):S373.
25. Stoehr T. Potent anti-tremor effects of lacosamide in a rat model for essential tremor [abstract]. Movement Dis. 2006; 21(suppl 15):S703.
26. Stohr T, Lekieffre D, Freitag J. Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats. Eur J Pharmacol. 2008;589(1-3):114-116.
27. Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23(2):150-158. (Pubitemid 46150939)
28. Biton V, Rosenfeld W, Mameniskiene R, et al. Multicenter, double-blind, doubledummy trial investigating safety, tolerability and pharmacokinetics of intravenous SPM 927 in subjects with partial seizures [abstract]. Epilepsia. 2006;47 (suppl 3):12-13.
29. Thomas D, Scharfenecker U, Schiltmeyer B, Doty P, Cawello W, Horstmann R. Low potential for drug-drug-interaction of lacosamide [abstract]. Epilepsia. 2006;47(suppl 4):200.
30. Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partialonset seizures. Epilepsia. 2008;49(3) 418-424. (Pubitemid 351294527)
31. Ben-Menachem E. Lacosamide- efficacy and safety results in adults with partial-onset seizures [abstract]. Epilepsia. 2007;48(suppl 7):176.
32. Chung SS, Sperling M, Biton V, Krauss G, Beaman M, Hebert D. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures [abstract]. Epilepsia. 2007;48 (suppl 6):321.
33. Halasz P, Kalvianen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Sullivan T. Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures [abstract]. Epilepsia. 2006;47(suppl 4):3.
34. Rosenfeld W, Fountain NB, Kaubrys G, Heinzen L, McShea C. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures [abstract]. Epilepsia. 2007;48(suppl 6):318-319.
35. Rosenfeld W, Fountain N, Kaubrys G, Heinzen L, McShea C. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures [abstract]. Eur J Neurol. 2008;15(suppl 3):13.
36. Krauss G, Ben-Menachem E, Mameniskiene R, Vaiciene N, Brock M, Whitesides J. Intravenous lacosamide (SPM 927) as replacement for oral laco - samide in subjects with partial seizures: a multicenter, open-label, inpatient safety and tolerability trial [abstract]. Epilepsia. 2006;47(suppl 4):163.
37. Vaiciene N, Mameniskiene R, Biton V, Brock M, Sommerville K. Multicenter open-label trial investigating safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures [abstract]. Epilepsia. 2006;47(suppl 3):146.
38. Krauss G, Ben-Menachem E, Mameniskiene R, Vaiciene N, Whitesides J, Brock M. Intravenous lacosamide as replacement for oral lacosamide in subjects with partial-onset seizures: a multicenter, open-label, inpatient safety and tolerability trial [abstract]. Neurology. 2007;68(suppl 1):A125.
39. Frye W, Simpson J, Shaibani A, Koch B; SP665 Study Group. The safety and efficacy of lacosamide in the long-term treatment of diabetic neuropathic pain [abstract]. Neurology. 2006;66(suppl 2):A203.
40. Shaibani A, Biton V, Rauck R, Koch B, Simpson J. Long-term oral lacosamide in painful diabetic neuropathy: a twoyear open-label extension trial [published online ahead of print July 10, 2008]. Eur J Pain. doi:10.1016/j.ejpain.2008.05.016.
41. Wymer J, Garrison C, Simpson J, Koch B; SP742 Study Group. A multicenter, randomized, double-blind, placebocontrolled trial to assess the efficacy and safety of lacosamide in subjects with painful distal diabetic neuropathy [abstract]. Neurology. 2006;66(suppl 2):A202.
42. Wymer J, Garrison C, Simpson J, Koch B. Efficacy and safety of lacosamide in painful distal diabetic neuropathy [abstract]. Diabetes. 2007;56(suppl 1):A158.
43. Shaibani A, Kenney P, Simpson J, Bongardt S. Lacosamide in painful distal diabetic neuropathy: results of a multicen ter, placebo-controlled US trial [abstract]. Eur J Neurology. 2007;14(suppl 1):250.
44. Graf R, Frye W, Simpson J. Lacosamide in long-term treatment of painful diabetic neuropathy (DNP) [abstract]. Eur J Neurol. 2007;14(suppl 1):260.
45. Bongardt S, Bain S, Tzschaschel B, Sommerville K. Lacosamide reduces pain in subjects with diabetic neuropathic pain [abstract]. Ann Neurol. 2008;64(suppl 12):S25.
46. Hidvegi T, Bretschneider M, Thierfelder S, Sommerville K, Bongardt S. Long-term efficacy of lacosamide in subjects with painful distal diabetic neuropathy [abstract]. Eur J Neurol. 2008;15 (suppl 3):324.
47. Krebsfaenger N, Stoehr T. Laco - samide, an investigational anticonvulsant, has a favorable profile in preclinical reproductive, developmental and juvenile toxicity studies [abstract]. Epilepsia. 2007;48(suppl 6):363-364.
48. Biton V, Fountain N, Rosenow F, et al. Safety and tolerability of lacosamide: summary of adverse events in epilepsy clinical trials [abstract]. Ann Neurol. 2008;64(suppl 12):S21.
49. Jatuzis D, Biton V, Ben-Menachem E, Abou-Khalil B, Doty P, Rudd GD. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures [abstract]. Epilepsia. 2005;46(suppl 8):170.
50. Kalviainen R, Halasz P, Mazurkiewicz-Beldzinska M, Rosenow F, Hoepken B, Rudd GD. Oral lacosamide: evaluation of effect on concomitant antiepileptic drug plasma concentrations in subjects with partial-onset seizures [abstract]. Eur J Neurol. 2007;14(suppl 1):86.
51. Thomas D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. Laco - samide has no potential for interaction with metformin [abstract]. Diabetes. 2007;56(suppl 1):A572.